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reduced quality of life, exacerbations, hospitalizations, and increased mortality.
What does this article add to our knowledge? Persistence to treatment for ﬁrst-time users of salmeterol/ﬂuticasone
propionate combination therapy is suboptimal. Inhaler devices, which differ in the technique required for correct drug
inhalation, may inﬂuence persistence behavior.
How does this study impact current management guidelines? These new data provide a basis for further research to
better understand persistence behavior and to develop strategies to address poor persistence.BACKGROUND: Low adherence and persistence to inhaled
therapy result in poor outcomes in patients with asthma and
chronic obstructive pulmonary disease (COPD). Although
adherence has been widely studied, growing awareness of the
large number of patients who abandon their asthma treatment
suggests that persistence to treatment may be more relevant for
longer term outcomes.
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884Diskus in patients with asthma or COPD aged 12 years and
above.
METHODS: This study analyzed dispensing data from a large
German pharmacy database. Male and female patients who were
prescribed AirFluSal Forspiro were randomly paired with those
who were prescribed Seretide Diskus controlling for month of
treatment initiation (to limit potential seasonality effects), age
groups, and gender. Matched patient pair analysis was
conducted on a total of 11,774 patients (45.1% male) to
compare persistence between the 2 products.
RESULTS: The survival probability estimates at 12 months
were 0.229 (0.02 standard error) for AirFluSal Forspiro versus
0.105 (0.025 standard error) for Seretide Diskus. The Renyi
family of tests demonstrated a statistically signiﬁcant difference
(P [ .01) in persistence to AirFluSal Forspiro compared with
Seretide Diskus in the overall survival experience of the 2
populations.
CONCLUSIONS: In this large retrospective pharmacy database
analysis, patients using AirFluSal Forspiro were more likely to
persist with treatment compared with those using Seretide
Diskus as demonstrated by the overall survival experience of the
2 populations (12-month study period). These new data provide
a basis for further research to better understand persistence
behavior and to develop strategies to address poor
persistence.  2016 The Authors. Published by Elsevier Inc.
on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/). (J Allergy Clin Immunol Pract 2016;4:884-9)
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COPD- Chronic obstructive pulmonary disease
ISPOR- The International Society for Pharmacoeconomics and
Outcomes Research
LABA- Long-acting b-adrenoceptor agonists
MPP-Matched patient pairAsthma and chronic obstructive pulmonary disease (COPD)
are chronic respiratory disorders that have a high global preva-
lence and are associated with signiﬁcant morbidity and mortality
worldwide.
Although effective treatments for both asthma and COPD are
available, low adherence and persistence result in poor patient
outcomes including symptoms, reduced quality of life, exacer-
bations, hospitalizations, and increased mortality, as well as a
substantial health care burden and high economic costs.1-4
Adherence and persistence to treatment are interrelated but
distinct concepts. The International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) deﬁnes adherence as
“the extent to which a patient acts in accordance with the pre-
scribed interval and dose of a dosing regimen,” and persistence as
“the duration of time from initiation to discontinuation of
therapy.”5 Persistence is a useful indication of patients’ behavior
over the long term. Evidence shows that many patients pre-
scribed drugs to treat chronic conditions discontinue therapy
well before the potential health beneﬁts can be realized.6
Lack of persistence to inhaled medication is a signiﬁcant
problem in people with asthma and COPD. One study reported
controller medication discontinuation rates of 43% among
patients with asthma.7 Strategies to address poor adherence may
differ from those that address lack of persistence, so it is crucial to
understand persistence behavior further. In one study of 5504
patients who ﬁlled an initial prescription for inhaled salmeterol/
ﬂuticasone propionate therapy, 59% never ﬁlled the prescription
again over a 12-month period; the number of patients
continuing to reﬁll their prescription decreased with time, with
only 9% still persisting at 12 months.8 The reasons behind poor
persistence in patients with asthma and COPD are complex, and
may include lack of symptoms, confusion around medications,
and difﬁculty in handling the inhaler device. A variety of inhaler
devices are used to deliver treatment for asthma and COPD, and
these differ in the technique required for correct drug inhalation.
The design of inhaler devices, in terms of both initial ease-of-use
and intuitive features that help to maintain a good inhaler
technique over time, may potentially inﬂuence persistence. To
date, there have been relatively few studies relating to persistence
of widely prescribed treatments for asthma and COPD,7,8 so this
is an area warranting further investigation. Information from
drug prescribing or dispensing databases has been used to study
adherence and persistence to treatment in large numbers of
patients across a wide range of therapy areas, including respira-
tory disease. Analysis of such data can provide valuable insights
into persistence to treatment over the long term.
The objective of the study was to compare persistence of
treatment to AirFluSal Forspiro with persistence to Seretide
Diskus in patients aged 12 years and above in a real-world
setting, using a matched patient pair (MPP) analysis. Anony-
mized data from a German pharmacy database were analyzed to
compare persistence to treatment with AirFluSal Forspirosalmeterol/ﬂuticasone propionate combination dry powder
inhaler (50 mg/500 mg) with persistence to treatment with
Seretide Diskus salmeterol/ﬂuticasone propionate combination
dry powder inhaler (50 mg/500 mg). Seretide Diskus is also
known as Viani and Atmadisc. The Diskus device is designed to
be “easy to use.” The AirFluSal Forspiro device has been spe-
ciﬁcally designed to be intuitive so that users can operate the
device correctly in the long term.9 Differences in device design
could potentially impact patient behavior.
METHODS
The research protocol was designed using the ISPOR checklist for
medication adherence and persistence studies using retrospective
databases.10
Data source
The data were obtained from the German supplier “INSIGHT
Health.” Established in 1999, INSIGHT Health is one of the
leading data providers in the German health care market and pro-
vides data from 4000 pharmacies, representing approximately 20%
of the total public pharmacies in Germany. Anonymized dispensing
data were obtained for patients treated with AirFluSal Forspiro or
Seretide Diskus. Both AirFluSal Forspiro and Seretide Diskus are
licensed for treatment of asthma and COPD; however, the patients’
speciﬁc diagnosis was not recorded in the pharmacy database.
Inclusion criteria
Male and female patients aged 12 years and above who were
prescribed AirFluSal Forspiro or Seretide Diskus were included in
the analysis. Analysis was conducted only for patients who were
naïve to ﬂuticasone propionate/salmeterol combination therapy (ie,
those who had not received a prescription for a study drug within the
6 months before the study period).
Exclusion criteria
Patients less than 12 years of age or those with missing
demographic data, such as for age and gender, were excluded from
the analysis.
Definition of persistence
Persistence was deﬁned as “the duration of time from initiation to
discontinuation of therapy” as per the ISPOR guidelines.10 Treat-
ment was classiﬁed as “continuing” if prescriptions were reﬁlled
within 30 days after the completion date of the previous prescrip-
tion. Treatment was recorded as “discontinued” if the prescription
was not ﬁlled within this time. If the additional 30 days exceeded the
end of the study timeframe (February 28, 2015) or if the patient still
had a medication supply, then the patients were censored and were
assumed to be still persisting to treatment. Patients who switched
products were deﬁned as “discontinuing” their therapy.
Statistical methods
Patients prescribed AirFluSal Forspiro were randomly paired with
those prescribed Seretide Diskus. Anonymized dispensing data were
obtained for patients treated with AirFluSal Forspiro between
February 2014 and February 2015, which represented the ﬁrst 13
months of product availability in Germany. For Seretide Diskus,
data collection was between February 2013 and February 2014. The
follow-up periods overlapped and the data sets did not differ by more
than 1 year. A total of 7178 patients received AirFluSal Forspiro
during the study period. Of these, 5887 patients were included in
the MPP analysis; 1291 did not meet the eligibility criteria because
TABLE I. Numbers of matched patients by age and gender
AirFluSal Forspiro
(N [ 5887)
Seretide Diskus/Viani/
Atmadisc (N [ 5887)
Total
(N [ 11,774)
Age group
12-20 155 155 310
21-30 478 478 956
31-40 574 574 1148
41-50 911 911 1822
51-60 1213 1213 2426
61-70 1072 1072 2144
71-80 1029 1029 2058
81-90 419 419 838
91þ 36 36 72
Gender
Female 3230 3230 6460 (54.9%)
Male 2657 2657 5314 (45.1%)
TABLE II. Numbers of matched patients by month of treatment
initiation
AirFluSal Forspiro
(N [ 5887)
Seretide Diskus/Viani/
Atmadisc (N [ 5887)
Total
(N [ 11,774)
February 135 135 270
March 188 188 376
April 200 200 400
May 170 170 340
June 112 112 224
July 411 411 822
August 341 341 682
September 461 461 922
October 673 673 1346
November 755 755 1510
December 707 707 1414
January 852 852 1704
February 882 882 1764
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analysis was conducted on a total of 11,774 patients to compare
persistence between the 2 products, controlling for month of initi-
ation (to limit the effect of seasonality on the ﬁndings), age groups,
and gender.
To test for differences in persistence of treatment, product and/or
device, age group, and gender were compared and the following
measures were reported: sample size, including percentage of
censored subjects; mean persistence, including 95% conﬁdence
intervals; Kaplan-Meier survival curves (representing persistence over
time); and P values derived from a nonparametric log-rank test
(Mantel-Cox test).
The log-rank tests the equality of the survival distributions for
AirFluSal Forspiro and Seretide Diskus. All time points are treated
equally. The null hypothesis was that there is no difference between
survival curves (ie, persistence to treatment with both products is
equal).
The log-rank test has optimum power under the assumption of
proportional hazard rates; however, this assumption is often violated
when 2 survival curves cross each other.11 As the Kaplan-Meier
survival curves crossed, the supremum (Renyi) family of tests,
designed to detect differences in survival curves that cross, were
subsequently performed to provide a more comprehensive analysis.
PATIENT DEMOGRAPHICS
In all, 5887 patients using AirFluSal Forspiro were paired with
5887 using Seretide Diskus. Table I shows the patient numbers
by age group and gender and Table II shows the patient numbers
by month.
RESULTS
At 6 months, the survival curves for persistence of treatment
for the 2 product groups started to separate (Figure 1). The
survival probability estimates at 12 months were 0.229 (0.02
standard error) for AirFluSal Forspiro versus 0.105 (0.025
standard error) for Seretide Diskus (Figure 1). The Renyi family
of tests demonstrated a statistically signiﬁcant difference (P ¼
.01) in persistence to AirFluSal Forspiro compared with Seretide
Diskus in the overall survival experience of the 2 populations
(Table III). The mean persistence in days was longer forAirFluSal Forspiro, 149.926 versus 134.228 for AirFluSal
Forspiro and Seretide Diskus, respectively (Table IV). A higher
proportion of patients using Seretide Diskus were prescribed 60
days’ treatment than for AirFluSal Forspiro; the proportion of
30-day prescriptions was 62.12% for AirFluSal Forspiro
compared with 50.23% for Seretide Diskus. This difference in
dispensing patterns may explain the apparent difference in
persistence seen between Seretide Diskus and AirFluSal Forspiro
in the ﬁrst 90 days. The aim of this study was to explore
persistence to treatment, to provide an indicator of overall
persistence of treatment over the long term.
DISCUSSION
A variety of inhaler devices are used to deliver treatment for
asthma and COPD. These differ in the technique required for
correct drug inhalation, which may inﬂuence adherence and
persistence to treatment.12,13 Although adherence relates to
conformity to recommendations about day-to-day treatment,
persistence refers to the act of continuing treatment for the
recommended duration.5 Several studies have reported high
levels of nonpersistence with inhaled medication for asthma and
COPD.7,8 The AirFluSal Forspiro device has been designed to be
easy to teach and to use and achieves preference ratings of more
than 90% in patients with asthma and COPD.9 In addition,
intuitive design cues have been incorporated to encourage correct
use of the device over the long term.9
This retrospective analysis of patients (N ¼ 11,774) included
in a large German dispensing database found that overall
persistence to treatment for ﬁrst-time users of ﬂuticasone pro-
pionate/salmeterol combination therapy was suboptimal.
Patients using AirFluSal Forspiro were more likely to persist with
treatment compared with those using Seretide Diskus as
demonstrated by the overall survival experience of the 2 pop-
ulations (12-month study period). As both asthma and COPD
are chronic conditions, it was important for this analysis to
investigate long-term persistence behavior in patients; therefore,
a 12-month time point was chosen to be appropriate from a
clinical perspective. The large sample size of 11,774 patients
means that this is a substantial real-world data study that pro-
vides relevant information to prescribers.
FIGURE 1. Kaplan-Meier survival (persistence) curve. The survival probability estimates at 12 months were 0.229 (0.02 standard error)
for AirFluSal Forspiro versus 0.105 (0.025 standard error) for Seretide Diskus.
TABLE III. Overall comparison of persistence: supremum (Renyi) family of tests
Weight X2 Classical Log-Rank P value Q - Renyi statistic Renyi family: P value
Log-Rank (Mantel-Cox) 11.36 0.001 10.2 0.01
Breslow (Generalized Wilcoxon) 62.4 <0.001 10.38 0.01
Tarone-Ware 42.025 <0.001 10.67 0.01
Fleming Harrington (p¼1, q¼1) 6.37 0.01
NA, not applicable.
TABLE IV. Mean persistence in days
Product
Mean* (d)
Estimate
Standard
error
95% confidence interval
Lower bound Upper bound
AirFluSal Forspiro 149.926 3.024 143.999 155.853
Seretide Diskus 134.228 2.867 128.608 139.848
Overall 142.111 2.137 137.923 146.300
*Estimation is limited to the largest survival time if it is censored.
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Information from drug prescribing or dispensing databases has
been shown to provide valuable insights into persistence of a
prescribed treatment.14 For example, in North America, claims
data have been used since the early 1980s for research pur-
poses.15 In Europe, medical records databases, such as the
General Practice Research Database,16 and administrative data,
such as the German Statutory Health Insurance claims data, areuseful sources for pharmacoepidemiology and health services
research.15 Use of such databases can enable measurement of
both the total duration of therapy and the intensity of medica-
tion taking, by measuring the interval between the date of the
ﬁrst prescription and the point at which the patient would have
had an insufﬁcient supply of available drug to cover the gap
between reﬁlls.6 Previous retrospective database studies have also
shown persistence rates among people with asthma and COPD
to be suboptimal.14,17,18 In a population-based cohort study of
patients with COPD starting a long-acting muscarinic antago-
nist, long-acting b-adrenoceptor agonists (LABA), or LABA-
inhaled corticosteroids ﬁxed-dose combination, only 21%-27%
of patients were persistent after 1 year.17 Similarly, low persis-
tence rates (5%-20%) were seen among patients with COPD
after 1 year in a Canadian prescription claims database analysis.19
The results reported here are consistent with these earlier ﬁnd-
ings, although direct comparison between studies with differing
methodologies is problematic.
Strengths of this study included the large patient numbers
included in the analysis and also the MPP design, which
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in treatment comparison. Furthermore, patients were matched
for month of treatment initiation, limiting the effect of season-
ality on the ﬁndings. Inclusion of patients who were naïve to
treatment for 6 months before the start of the study allowed the
impact of speciﬁc treatments on persistence behavior to be
assessed.
Although database analyses are a well-accepted methodology,
there are limitations. For example, prescription reﬁll data do not
provide information about actual daily medication use; they
simply provide evidence of the extent to which patients obtain
their medicines.8 In addition, the data source was such that the
speciﬁc indication for which AirFluSal Forspiro or Seretide
Diskus had been prescribed was not known; however, both
products are licensed for asthma and COPD. It was also not
possible to identify speciﬁc health centers at which patients
received their care or to determine the social background of
patients, and the database covered only approximately 20% of
the total public pharmacies in Germany. As the anonymized
pharmacy data could not be linked to patient records, it was not
possible to examine outcomes in relation to treatment persis-
tence. Several studies have previously shown the link between
suboptimal adherence to poor health outcomes among people
with asthma and COPD.20,21
At this stage, the reasons for longer persistence to AirFluSal
Forspiro compared with Seretide Diskus are unclear and further
research is required to establish the underlying reasons for this
ﬁnding. The AirFluSal Forspiro (ﬂuticasone propionate/salme-
terol; Sandoz, International GmbH, Germany) device has been
designed to be easy to teach and to use9 and achieves preference
ratings of more than 90% in patients with asthma and COPD.9
In addition, intuitive design cues have been incorporated to
encourage the correct use of the device over the long term,9
which may encourage persistence to therapy. Furthermore,
although several studies have investigated strategies to improve
adherence to inhaled medication,4 long-term persistence to
treatment is a different concept and may require different
interventions.CONCLUSIONS
Although effective treatments for asthma and COPD are
available, lack of adherence and low persistence may result in
poor patient outcomes including symptoms, reduced quality of
life, exacerbations, hospitalizations, and increased mortality, as
well as a burden on health care systems and high economic
costs.
An apparently easy-to-use device still requires the clinician to
provide a clear, initial demonstration and the inhaler technique is
known to deteriorate over time.22 In addition, intuitive device
design may aid consistently a good inhaler technique over the
long term, potentially promoting persistence.
Analyses of large prescribing and dispensing databases can
provide valuable insights into patient behavior. In this initial,
retrospective pharmacy database analysis, patients using Air-
FluSal Forspiro were more likely to persist with treatment
compared with those using Seretide Diskus as demonstrated by
the overall survival experience of the 2 populations (12-month
study period). Accepting the limitations of this type of analysis,
these new data provide a basis for further investigation and
research, which could involve using other national databaseswith the capability to link drug utilization to respiratory disease
outcomes. These data are supported by previous retrospective
database analyses that have concluded that persistence to
inhaled treatment among patients with asthma and COPD is
poor, and further strategies to address poor persistence are
required.
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